
Prof. em. Dr. Dr. h.c. Detlev Riesner
Chairman
Prof. Dr. Detlev Riesner
Professor Dr. Riesner held the chair of Biophysics at Heinrich Heine University in Düsseldorf from 1980 to 2006, was dean of the Science Faculty and prorector of research. Since his retirement in 2006, he was member of the board of trustees of Heinrich Heine University until 2017. During his academic career Professor Dr. Riesner worked as a research assistant at Princeton University and as a visiting professor at the University of California, San Francisco and Academia Sinica (China). Professor Dr. Riesner is a co-founder of Qiagen N.V., member of the Supervisory Board and held the position as Chairman of the Supervisory Board from 1999 to 2014. He was also a member of the Supervisory Boards of NewLab Bioquality AG, Erkrath, Drevo AG, Cologne, Alantos AG, Heidelberg and AC Immune, Lausanne. Furthermore, Professor Riesner was a member of the Scientific Advisory Board of the Friedrich-Löffler Institute, Isle of Riems and PrioNet and APRI, both in Canada. He received awards from the Federal Government, from the State of NRW and the Max Planck Society. Prof. Dr. Riesner works with Priavoid as a business angel, partner and mentor.

Rolf Hoffmann
Deputy Chairman
Rolf Hoffmann
Rolf Hoffmann is an internationally experienced leader in the pharmaceutical and biotech industry. After studying English philology and sports science at the University of Cologne and earning an MBA from the Kenan Flagler Business School (University of North Carolina, Chapel Hill), he held senior management positions at Eli Lilly (1987-2004) and Amgen (2004-2016). Since retiring from Amgen in 2016 he has built a significant portfolio of global board mandates. His professional expertise lies particularly in the fields of commertial operations and marketing for pharmaceutical and medical products and the management of life science companies. Among other things, he is involved as a strategic advisor to companies in the healthcare industry and as a lecturer at the University of North Carolina. He brings a strong international network to the development of innovative therapies for neurodegenerative diseases and has been a consultant for Priavoid for several years.